Loading quotes...

Forecast

The analysts' average price target is €50.05 (+16.88%). The median is €50.50 (+17.94%).

Buy
  5
Hold
  1
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • HeartFlow: plaque analysis becomes main growth driver

    HeartFlow presented plaque analysis as its most important near-term growth driver at the Wells Fargo conference and projects about $30 million in revenue for 2026 versus $1.5 million in 2025. In Q2 2026 revenue rose 48% to over $64 million with a gross margin of roughly 82%. The company has about $250 million in cash, aims for profitability by mid-2028, and sees an expanded addressable market from $5 billion to $11 billion through expansion into asymptomatic high-risk patients; a broader product rollout including PCI Navigator is planned for 2027. » More on de.investing.com


  • Heartflow climbs to new record high of $51.26

    Heartflow stock reached an all-time high of $51.26 after strong gains in recent months (about +110% in 6 months, +73% year-to-date). In Q2 2026 the company reported adjusted earnings of -$0.07 per share and revenue up 48% to $64.1 million, with both metrics beating estimates. In response, Stifel raised its price target to $45.00 and reiterated a "Buy" rating, while some valuations consider the stock overvalued relative to fair value. » More on de.investing.com


  • Heartflow hits record high of $48.70 after strong Q2 results

    Heartflow shares rose to a record high of $48.70, about 1% below the 52-week high; the stock is up 86% over the past six months. In Q2 2026 the company beat expectations with adjusted EPS of -$0.07 (estimate -$0.19) and revenue rising 48% to $64.1 million. Stifel raised its price target to $45.00 and affirmed its "Buy" rating, while InvestingPro notes the stock may be overvalued at current levels. » More on de.investing.com


  • HeartFlow beats Q2 expectations, raises full-year guidance and stock jumps after hours

    HeartFlow reported an adjusted loss per share of $0.07 for Q2 2026, beating consensus by $0.12. Revenue rose 48% to $64.1 million and gross margin climbed to 83.3%, driven by strong plaque business and AI-powered automation. The company raised its full-year guidance to $246–250 million in revenue and a non-GAAP gross margin of about 82%; the stock rose roughly 16–17% after hours. While HeartFlow remains unprofitable, it expects to be cash-flow positive by mid-2028 and is showing accelerated revenue and margin growth. » More on de.investing.com


  • HeartFlow beats Q1 forecasts, raises full-year outlook — shares slightly weaker

    HeartFlow reported Q1 2026 EPS of -$0.16, beating the expected -$0.22; revenue rose 41% to $52.6 million. Non-GAAP gross margin improved to 80.5% and the non-GAAP net loss narrowed to $13.3 million. The company received positive feedback on new products such as the PCI Navigator and raised its 2026 revenue guidance to $228–232 million. Despite the results, the stock slipped 0.61% in after-hours trading. » More on de.investing.com

Financials

In the last quarter, HeartFlow had revenue of €64.32m and net profit of -€10.16m
(EUR) September 2026
YoY
Revenue 64.32m 63.12%
Gross profit 53.78m 78.21%
Net profit -10.16m 76.56%
EBITDA -10.13m 73.74%

Fundamentals

Metric Value
Market capitalization
€3.73bn
Number of shares
87.89m
52-week high/low
€55.20 - €18.32
Dividends No
Beta
2.02
P/E ratio
-50.70
PEG ratio
-0.81
P/B ratio
14.40
P/S ratio
17.18

Company profile

HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company's platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. The company was founded in 2007 and is headquartered in Mountain View, California.

Name
HeartFlow
CEO
John Farquhar
Website
IPO
07/08/2025
Employees 843
🍪

Parqet  uses cookies. Learn more